Home›Legal›CJC-1295 in Texas
CJC-1295 in Texas: Legal Status & Provider Guide (2026)
Quick Answer
CJC-1295 is a prescription substance in the United States. CJC-1295 is a synthetic GHRH analog with no FDA approval and no bulk compounding authorization. Federal compliance for compounding facilities is uncertain. Clinical use occurs in a regulatory gray area. In Texas, compounding is governed by the Texas State Board of Pharmacy (TSBP). In Texas, physician assistants and nurse practitioners with prescriptive authority can prescribe compounded medications including peptides. Prescribers must hold an active Texas license. Telemedicine prescribing of controlled substances and certain compounded medications is permitted under Texas Medical Board rules with specific conditions.
Federal Legal Status
FDA Approval Status
Not FDA-approved. Not on the FDA 503A or 503B bulk substances lists. CJC-1295 (with or without DAC) is an unapproved research peptide.
Compounding Pharmacy Rules (Federal)
CJC-1295 is not on the FDA bulk substances list for 503A or 503B compounding. FDA has issued guidance indicating that unapproved peptides like CJC-1295 may not be lawfully compounded by facilities subject to FDA oversight. Providers offering it operate in a legally uncertain space under federal law.
Also Known As
Modified GRF (1–29) · Mod GRF 1–29 · DAC:GRF
Primary Research Areas
- Growth hormone release
- Anti-aging
- Body composition
- Muscle recovery
Texas Pharmacy Board & Compounding Rules
Regulator
Compounding Overview
Texas is home to one of the largest compounding pharmacy industries in the country, with detailed rules set by the Texas State Board of Pharmacy (TSBP). Texas 503A pharmacies may compound non-FDA-approved peptides under certain conditions, though federal FDA guidance takes precedence for pharmacies participating in the national regulatory framework. Texas-specific rules address sterile compounding standards, USP 797 compliance, and registration requirements for non-resident pharmacies shipping into the state.
Notable Rules
- Texas TSBP requires sterile compounding facilities to comply with USP 797 standards.
- Non-resident (out-of-state) pharmacies shipping compounded products into Texas must be registered with the TSBP.
- Texas prohibits the sale of prescription-only compounded products without a valid prescription.
- The Texas Medical Board regulates prescribing standards for telemedicine encounters including peptide programs.
Prescribing Requirements in Texas
In Texas, physician assistants and nurse practitioners with prescriptive authority can prescribe compounded medications including peptides. Prescribers must hold an active Texas license. Telemedicine prescribing of controlled substances and certain compounded medications is permitted under Texas Medical Board rules with specific conditions.
About CJC-1295
CJC-1295 is a synthetic analog of GHRH designed for extended half-life through Drug Affinity Complex (DAC) technology. The DAC version binds to albumin in the bloodstream, extending its half-life significantly compared to sermorelin. It is often studied in combination with ipamorelin.
For more research information, mechanism of action, and provider availability, see the CJC-1295 research profile on PeptideBase.
Frequently Asked Questions
- What is the difference between CJC-1295 with DAC and without DAC?
- CJC-1295 with DAC binds to albumin and has a half-life of approximately 1–2 weeks, allowing less frequent dosing. CJC-1295 without DAC (also called Modified GRF 1-29) has a much shorter half-life of approximately 30 minutes, similar to sermorelin, and requires more frequent administration.
CJC-1295 Providers in Texas
No providers currently listed in Texas for CJC-1295. Browse the full directory to find providers offering CJC-1295.
Browse all CJC-1295 providers →CJC-1295 Legal Status in Other States
Pharmacy board rules and compounding regulations vary by state. Compare CJC-1295 legal status across other major markets:
Content review: This educational overview is prepared by the PeptideBase editorial team and reviewed for factual accuracy. Reviewer byline coming soon (gated on 4.4). Last updated: .